Old drug, new hope? emetine trial targets dengue deaths

NCT ID NCT07016321

Not yet recruiting Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug emetine can help people hospitalized with dengue fever. About 600 adults aged 18 to 65 will take either a low or high dose of emetine or a placebo pill for 7 days. Researchers will track if the drug reduces deaths or stops the disease from becoming severe, and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Emetine hydrochloride (an oral drug)
What this could lead to: If it works, this could provide a new treatment to prevent severe dengue and reduce deaths from the disease.
What could go wrong: This is an early combined phase 2/3 trial, so results are uncertain. Emetine may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dengue disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DENGUE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bharatpur Hospital

Bharatpur-10, Chitwan, Nepal

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Johns Hopkins University, Division of Infectious Disease

Baltimore, Maryland, 21231, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.